# US 2025/0367246 A1 · Immunomodulatory compositions comprising microbial entities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367246 A1
- Document ID: US20250367246A1
- Status: Published application
- Kind: A1
- Application number: 19/304,337
- Filed: 2025-08-19
- Published: 2025-12-04
- Earliest claimed: 2021-12-21
- Assignees: Solarea Bio, Inc.
- Applicants: Solarea Bio, Inc.
- Inventors: Eric Michael Schott; Gerardo V. Toledo; Maria Juliana Soto-Giron; Alicia Eve Ballok; Ryan Green; Mark Charbonneau
- Web page: https://patentgrep.com/patent/US20250367246A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/15: Vitamins
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 36/06: Fungi, e.g. yeasts
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.

## Claims

### Claim 1

A composition formulated for oral administration comprising a combination of at least two heterologous microbes selected from Lactobacillus harbinensis, Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, and wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs: 43, 198, 221, and 224, formulated in an amount effective to produce an anti-inflammatory effect in a human subject.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a prebiotic selected from the group consisting of oligofructose, a dried fruit or vegetable powder, and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising one or more vitamins, wherein the one or more vitamins are selected from the group consisting of vitamins A, B6, B12, C, D, E, K1, K2, riboflavin, niacin, folic acid, pyridoxine, thiamine, pantothenic acid, biotin, and combinations thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein producing an anti-inflammatory effect in a mammalian subject comprises reducing the level and/or activity of at least one inflammatory cytokine selected from Table 8 relative to a level and/or activity of the inflammatory cytokine in the serum of the subject; or a tissue of the subject, prior to administering the composition to the subject.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the anti-inflammatory effect in a mammalian subject is caused by the production of at least one anti-inflammatory metabolite selected from the group consisting of indole, indole acetic acid (IAA), indole propionic acid (IPA), bacteriocins, antibacterial peptides, serotonin, gamma-aminobutyric acid (GABA), dopamine, melatonin, secondary bile acids, and combinations thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein administering an effective amount of the composition to a human subject enables the dietary management of at least one symptom in the subject of a rheumatic disease selected from rheumatoid arthritis, spondyloarthritis, and psoriasis.

### Claim 7 (depends on 6)

The composition of claim 6, further comprising administering one or more additional agents for the treatment or management of one or more symptoms of rheumatic disease.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the one or more additional agents comprises methotrexate.

### Claim 9 (depends on 1)

The composition of claim 1, wherein administering an effective amount of the composition to a human subject enables the dietary management of at least one symptom of aging-associated inflammation in a human subject.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition comprises at least three heterologous microbes selected from Lactobacillus harbinensis, Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis.

### Claim 11

A composition formulated for oral administration comprising a combination of at least two heterologous microbes selected from Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, and wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs: 43, 198, and 224, formulated in an amount effective to produce an anti-inflammatory effect in a human subject.

### Claim 12 (depends on 11)

The composition of claim 11, further comprising a prebiotic selected from the group consisting of oligofructose, a dried fruit or vegetable powder, and combinations thereof.

### Claim 13 (depends on 11)

The composition of claim 11, further comprising one or more vitamins, wherein the one or more vitamins are selected from the group consisting of vitamins A, B6, B12, C, D, E, K1, K2, riboflavin, niacin, folic acid, pyridoxine, thiamine, pantothenic acid, biotin, and combinations thereof.

### Claim 14 (depends on 11)

The composition of claim 11, wherein producing an anti-inflammatory effect in a human subject comprises reducing the level and/or activity of at least one inflammatory cytokine from Table 8 relative to a level and/or activity of the inflammatory cytokine in the serum of the subject; or a tissue of the subject, prior to administering the composition to the subject.

### Claim 15 (depends on 11)

The composition of claim 11, wherein administering an effective amount of the composition to a human subject enables the dietary management of at least one symptom in the subject of a rheumatic disease selected from rheumatoid arthritis, spondyloarthritis, and psoriasis.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the composition comprises Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis.

### Claim 17

A composition formulated for oral administration comprising a combination of at least two heterologous microbes comprising Lactobacillus brevis and Lactococcus lactis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs: 43 and 224 formulated in an amount effective to produce an anti-inflammatory effect in a human subject.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising a prebiotic selected from the group consisting of oligofructose, a dried fruit or vegetable powder, and combinations thereof.

### Claim 19 (depends on 17)

The composition of claim 17, further comprising one or more vitamins, wherein the one or more vitamins are selected from the group consisting of vitamins A, B6, B12, C, D, E, K1, K2, riboflavin, niacin, folic acid, pyridoxine, thiamine, pantothenic acid, biotin, and combinations thereof.

### Claim 20 (depends on 17)

The composition of claim 17, wherein producing an anti-inflammatory effect in a human subject comprises reducing the level and/or activity of at least one inflammatory cytokine from Table 8 relative to a level and/or activity of the inflammatory cytokine in the serum of the subject; or a tissue of the subject, prior to administering the composition to the subject.
